Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients

Clinical Infectious Diseases

Volumn 35, Issue 3, 2002, Pages 228-235

  Hanes, Scott D ^a   Demirkan, Kutay ^d,e   Tolley, Elizabeth ^b   Boucher, Bradley A ^a   Croce, Martin A ^c   Wood, G Christopher ^a   Fabian, Timothy C ^c  

^a University of Pharmacy   (United States)

^b Departments of Biostatistics   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d Baptist Memorial Hospital   (United States)

^e HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; SULTAMICILLIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; CORRELATION ANALYSIS; CRITICAL ILLNESS; DISEASE SEVERITY; FEMALE; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LUNG CONTUSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; STENOTROPHOMONAS MALTOPHILIA; TRACHEOSTOMY; TRAFFIC ACCIDENT; TREATMENT PLANNING;

ADULT; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; CROSS INFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; RISK FACTORS; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 0036680474     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/341022     Document Type: Article

References (34)

1. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999)
2. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas mahophilia) in patients with cancer
3. Characteristics of Xanthomonas infections in critically ill surgical patients
4. Xanthomonas maltophilia and Pseudomonas cepacia in lower respiratory tracts of patients in critical care units
5. Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive care unit defined by restriction fragment-length polymorphism typing
6. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia
7. The effect of late-onset ventilator-associated pneumonia in determining patient mortality
8. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia
9. The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia
10. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains
11. Nosocomial infection caused by Xanthomonas maltophilia: A case-control study of predisposing factors
12. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis
13. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients
14. Utility of Gram's stain and efficacy of quantitative cultures for posttraumatic pneumonia
15. Nosocomial pneumonia: Importance of recognition of aetiological agents to define an appropriate initial empirical coverage
16. Using bronchoalveolar lavage to distinguish nosocomial pneumonia from systemic inflammatory response syndrome: A prospective analysis
17. Assessment of coma and impaired consciousness
18. The injury severity score: A method for describing patients with multiple injuries and evaluating emergency care
19. Rating the severity of tissue damage. I. The abbreviated scale
20. APACHE II: A severity of disease classification system
21. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome
22. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens
23. Nosocomial infection and colonization by S. maltophilia: Analysis of risk factors and etiology by DNA-fingerprint
24. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals: A study of 143 patients
25. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen
26. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: A historical cohort study
27. Identification of early predictors for post-traumatic pneumonia
28. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital
29. Attributable mortality of Stenotrophomonas maltophilia bacteremia
30. Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies
31. Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999
32. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods
33. Comparative activities of isepamicin, amikacin, cefepime, and ciprofloxacin alone or in combination with other antibiotics against Stenotrophomonas maltophilia